is the brand name of
it has demonstrated has first drug to treat the HCV infection by safety and efficacy treatment, without the requirement of interferon co administration. Sofosbuvir only drug used with combination of ribavirin, peginterferon-alfa, Velpatasvir, daclatasvir, ledipasvir, simeprevir. It is administrated by orally. Sofosbuvir has high cure rate in genotypes about 90% overall response rate. To prevent Hep C virus, its first regimen to awaiting liver transplantation for the patients.
For use in Genotypes 1,2,3 and 4 sofosbuvir are approved and it’s the first most orally treating regimen for genotypes 2 or 3. Sofosbuvir requires 12 weeks course of therapy for most patient. And Strength of 400 mg, once daily.
Sofosbuvir with ribavirin combination should be used for the treatment of CHC patient with liver cancer (hepatocellular carcinoma) in which can keep pending liver transplantation for up to 48 weeks or can inhibit post-transplant HCV infection until liver transplant.
USES OF SOFOSBUVIR:
It is used for the treatment of HCV in initial stage and coimbination with another drug for HCV genotypes 1,2,3,4,5 and 6 by all part of first line therapy. On second line therapy,Sofosbuvir combination with Velpatasvir have cure rate higher than 90% is recommended for all genotypes. Duration of therapy mostly of 12 weeks. Based on perspective, cost-effectiveness is also used for longer treatment with other medication.
It also used prior to failed treatment,who have experienced failure treatment with other form of combination therapy for hepatitis C Infection, thereby next possible way by retreatment with Sofosbuvir. Retreatment Duration is 12-24 weeks depends upon medicine used, in case patient ihas liver cirrhosis or not.